CD30/TNFRSF8 Antibody (Ki-1/779), Novus Biologicals™

Mouse Monoclonal Antibody

Supplier:  Novus Biologicals NBP2445610.1MG

Catalog No. NBP24456101

Description

Ensure accurate, reproducible results in Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

CD30/TNFRSF8 Monoclonal specifically detects CD30/TNFRSF8 in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence.

Specifications

• Antigen: CD30/TNFRSF8
• Classification: Monoclonal
• Concentration: 0.2mg/mL
• Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, SDS-Page, Immunofluorescence 1 - 2 ug/ml
• Gene Accession No.: P28908
• Gene Symbols: TNFRSF8
• Immunogen: Recombinant human TNFRSF8 protein
• Quantity: 0.1 mg
• Research Discipline: Apoptosis, Cell Cycle and Replication, Embryonic Stem Cell Markers, Immunology, Stem Cell Markers
• Gene ID (Entrez): 943
• Target Species: Human
• Form: Purified

• Applications: Flow Cytometry, Immunohistochemistry (Paraffin), SDS-Page, Immunofluorescence
• Clone: Ki-1/779
• Conjugate: Unconjugated
• Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
• Gene Alias: CD30, CD30 antigen, CD30KI-1, CD30L receptor, cytokine receptor CD30, D1S166EKi-1, Ki-1 antigen, Lymphocyte activation antigen CD30, tumor necrosis factor receptor superfamily member 8, tumor necrosis factor receptor superfamily, member 8
• Host Species: Mouse
• Purification Method: Protein A or G purified
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Test Specificity: Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkins disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).
• Content And Storage: Store at 4C.
• Isotype: IgG1 κ

For Research Use Only